Role of Potassium-Competitive Acid Blockers in Helicobacter pylori Eradication
The first-line therapy for Helicobacter pylori infection comprises triple therapy with the combination of a proton pump inhibitor (PPI), amoxicillin, and clarithromycin. However, the H. pylori eradication rate after PPI-based triple therapy has fallen below 80% in many countries, and even reached 70...
Saved in:
| Main Author: | Jong Kyu Park |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean College of Helicobacter and Upper Gastrointestinal Research
2017-03-01
|
| Series: | The Korean Journal of Helicobacter and Upper Gastrointestinal Research |
| Subjects: | |
| Online Access: | http://www.helicojournal.org/journal/view.html?doi=10.7704/kjhugr.2017.17.1.20 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research progress of potassium-competitive acid blockers in the treatment of Helicobacter pylori
by: Zhaoli Ma, et al.
Published: (2025-12-01) -
Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon‐HP trial
by: William D Chey, et al.
Published: (2024-11-01) -
Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers
by: Jong Kyu Park
Published: (2023-09-01) -
Role of Potassium-competitive Acid Blockers in the Treatment of Gastric Acid-related Disorders
by: Mun Young Cho, et al.
Published: (2023-09-01) -
Clinical pharmacokinetics of potassium competitive acid blockers: a systematic review and meta-analysis
by: Jiaqi Liu, et al.
Published: (2025-07-01)